Data

A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia (AMLM21)

Health Data Australia Contributor Records
Wei, Andrew ; Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) ; Australasian Leukaemia and Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/E78K-5034&rft.title=A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia (AMLM21)&rft.identifier=http://doi.org/10.58109/E78K-5034&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=This dataset includes data for ALLG AMLM21 trial participants (19 male, 14 female, ages 24-87) with FLT3-ITD or CBL mutant AML (except Acute Promyelocytic Leukaemia) failing prior chemotherapy (i.e. relapsed or refractory) or who are considered unfit for frontline intensive chemotherapy, taking part in the PHASE Ib/II AMLM21 study. Data for the single treatment ARM is available (Ponatinib plus azacitidine). Participants were recruited at sites Australia wide, and includes data from treatment until disease progression, and up to a 5 year period in follow up. The study commenced in 2016 and conducted the last patient last visit in 2025. Dataset includes Timepoints at screening, end of each cycle up to cycle 24 and at relapse, Correlative samples (Collected), QOL (Collected, via EQ-5D and QLQ-C30). Cancer Australia demographic data: • Year of birth&rft.creator=Wei, Andrew &rft.creator=Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia and Lymphoma Group (ALLG) &rft.date=2026&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12614000810617&rft_rights=This dataset is currently under embargo. The dataset is expected to be available on approximately 01/10/2026. Data requests are being accepted, with the proviso that data will only be shared following the primary publication and all other restrictions being met.&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft.type=dataset&rft.language=English Access data via landing page
Cite Saved to MyRDA Save to MyRDA

Licence & Rights:

view details

This dataset is currently under embargo. The dataset is expected to be available on approximately 01/10/2026. Data requests are being accepted, with the proviso that data will only be shared following the primary publication and all other restrictions being met.

Access:

Other

Full description

This dataset includes data for ALLG AMLM21 trial participants (19 male, 14 female, ages 24-87) with FLT3-ITD or CBL mutant AML (except Acute Promyelocytic Leukaemia) failing prior chemotherapy (i.e. relapsed or refractory) or who are considered unfit for frontline intensive chemotherapy, taking part in the PHASE Ib/II AMLM21 study. Data for the single treatment ARM is available (Ponatinib plus azacitidine). Participants were recruited at sites Australia wide, and includes data from treatment until disease progression, and up to a 5 year period in follow up. The study commenced in 2016 and conducted the last patient last visit in 2025. Dataset includes Timepoints at screening, end of each cycle up to cycle 24 and at relapse, Correlative samples (Collected), QOL (Collected, via EQ-5D and QLQ-C30). Cancer Australia demographic data: • Year of birth

Notes

HeSANDA 1.0.0

Available: 2026-10-01

Issued: 2026

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
Cancer therapy (excl. chemotherapy and radiation therapy) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers